Announcements

Conference: 2024 CAMO Annual Scientific Meeting

Date: 24–26 October 2024

Location: Ottawa, ON, Canada

The Canadian Association of Medical Oncologists (CAMO) is a national specialty society of the Royal College of Physicians and Surgeons of Canada. Their mission is to contribute to cancer control, through research, education, and clinical practice in prevention, screening, diagnosis, treatment, supportive care, palliative care, and rehabilitation. The Association is committed to achieving and maintaining, among its members, excellence in clinical and scholarly activity, within a culture of compassion and respect for human dignity. CAMO Annual Scientific Meetings have been held since 2014.

The following MDPI journals will be represented at the 2024 CAMO Annual Scientific Meeting:

• Current Oncology;
• Cancers;
• Life;
• Onco;
• Women;
• Journal of Personalized Medicine;
• Journal of Molecular Pathology.

Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://camo-acom.ca/page-1549450.

World Lung Cancer Day is marked on 1st August every year with the aim of raising awareness about lung cancer and promoting prevention, screening, and treatment. This global event seeks to increase public understanding of the risk factors associated with lung cancer and drive governments, organizations, and individuals to take action in order to reduce the incidence and mortality rates of lung cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the related fields published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150

“ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57

“Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24

“Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer”
by Marco Bertolini, Valeria Trojani, Andrea Botti, Noemi Cucurachi, Marco Galaverni, Salvatore Cozzi, Paolo Borghetti, Salvatore La Mattina, Edoardo Pastorello, Michele Avanzo et al.
Curr. Oncol. 2022, 29(8), 5179–5194; https://doi.org/10.3390/curroncol29080410
Available online: https://www.mdpi.com/1718-7729/29/8/410

“Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer”
by Steven Olsen, Jiemin Liao and Hidetoshi Hayashi
Curr. Oncol. 2022, 29(7), 4811–4826; https://doi.org/10.3390/curroncol29070382
Available online: https://www.mdpi.com/1718-7729/29/7/382

“Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options”
by Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Thomas Zilli, Francesco Martucci, Luca Bonomo, Filippo Del Grande, Monica Casiraghi, Filippo De Marinis et al.
Curr. Oncol. 2023, 30(3), 3160–3175; https://doi.org/10.3390/curroncol30030239
Available online: https://www.mdpi.com/1718-7729/30/3/239

“Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices”
by Brandon S. Sheffield, Kiefer Eaton, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison, Andrea L. Stevens, Emmanuel M. Ewara and Parneet Cheema
Curr. Oncol. 2023, 30(2), 2348–2365; https://doi.org/10.3390/curroncol30020180
Available online: https://www.mdpi.com/1718-7729/30/2/180

“Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives”
by Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, Martina Di Pietro, Andrea Squeri, Maria Ilenia Passalacqua, Silvia Marchesi, Vanesa Gregorc and Mariacarmela Santarpia
Curr. Oncol. 2023, 30(4), 3684–3696; https://doi.org/10.3390/curroncol30040280
Available online: https://www.mdpi.com/1718-7729/30/4/280

Relevant Special issue:
“Current State of Immunotherapy for Lung Cancer”
Guest Editor: Prof. Dr. Barbara Melosky

You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.

Current Oncology Editorial Office

This year marks the 30th anniversary of Current Oncology (ISSN: 1718-7729), a peer-reviewed open access journal on clinical oncology. With an Impact Factor of 2.8 and a CiteScore of 3.3, the journal is covered in Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. The journal has published more than 4,100 papers from more than 17,200 authors, who are from 101 countries. This breakthrough could not have been achieved without our readers, authors, peer reviewers, editors, and all the people working for the journal who have combined their tremendous efforts over the years.

We invite you to explore our dedicated webpage, where you will find special content commemorating this milestone: https://www.mdpi.com/journal/curroncol/anniversary.

We have prepared a video showcasing the evolution of Current Oncology and featuring warm congratulations from our Editor-in-Chief, Prof. Dr. Shahid Ahmed.

30th Anniversary Special Issue:
“The 30th Anniversary of Current Oncology: Perspectives in Clinical Oncology Practice”

If you have any questions, suggestions, or recommendations, please do not hesitate to contact us at currentoncology@mdpi.com.

Current Oncology Editorial Office

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy | Editorial | view inaugural issue	anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article
	Dr. Giovanni E. Cacciamani, University of Southern California, USA | Editorial | view inaugural issue	surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article
	Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain | Editorial | view inaugural issue	laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article
	Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA | Editorial | view inaugural issue	companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article
	Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy | Editorial | view inaugural issue	real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.

July is Sarcoma and Bone Cancer Awareness Month, which is an important campaign dedicated to increasing the awareness and understanding of these unique and challenging diseases. Sarcomas are a rare group of cancers that originate in the bones or soft tissues of the body. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and high-quality Special Issues in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.

“Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment”
by Matthew Ho, Alexander Xiao, Dongni Yi, Saurabh Zanwar and Giada Bianchi
Curr. Oncol. 2022, 29(11), 8975-9005; https://doi.org/10.3390/curroncol29110705
Available online:  https://www.mdpi.com/1718-7729/29/11/705

“Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155-4177; https://doi.org/10.3390/curroncol29060332
Available online:  https://www.mdpi.com/1718-7729/29/6/332

“Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases”
by Claudio Pusceddu, Davide De Francesco, Nicola Ballicu, Domiziana Santucci, Salvatore Marsico, Massimo Venturini, Davide Fior, Lorenzo Paolo Moramarco and Eliodoro Faiella
Curr. Oncol. 2022, 29(8), 5891-5900; https://doi.org/10.3390/curroncol29080465
Available online:  https://www.mdpi.com/1718-7729/29/8/465

“Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma”
by Tanner Mack and Bibianna Purgina
Curr. Oncol. 2022, 29(9), 6400-6418; https://doi.org/10.3390/curroncol29090504
Available online:  https://www.mdpi.com/1718-7729/29/9/504

“Staging Systems and Nomograms for Soft Tissue Sarcoma”
by Maria Danieli and Alessandro Gronchi
Curr. Oncol. 2023, 30(4), 3648-3671; https://doi.org/10.3390/curroncol30040278
Available online:  https://www.mdpi.com/1718-7729/30/4/278

“Surgical Management of Retroperitoneal Sarcoma”
by Dana A. Dominguez, Sagus Sampath, Mark Agulnik, Yu Liang, Bao Nguyen, Vijay Trisal, Laleh G. Melstrom, Aaron G. Lewis, Isaac Benjamin Paz, Randall F. Roberts et al.
Curr. Oncol. 2023, 30(5), 4618-4631; https://doi.org/10.3390/curroncol30050349
Available online:  https://www.mdpi.com/1718-7729/30/5/349

The list of relevant Special Issues is as follows:

“Treatment of Bone Metastasis”
Guest Editor: Dr. Costantino Errani
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis

“Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment”
Guest Editors: Dr. Andrea Sambri, Dr. Michele Fiore and Dr. Massimiliano De Paolis
Available online: https://www.mdpi.com/journal/curroncol/special_issues/COMBGQV12M

“What’s New in Musculoskeletal Oncology?”
Guest Editors: Dr. Andreas F. Mavrogenis, Dr. Costantino Errani and Dr. Shinji Tsukamoto
Available online: https://www.mdpi.com/journal/curroncol/special_issues/J418745AG0

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.

Current Oncology Editorial Office

We are pleased to share that the Current Oncology (ISSN: 1718-7729) was awarded an increased Impact Factor of 2.8 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. The Current Oncology ranks upgraded from Q3 to Q2 (157 among 322 titles) in the “Oncology” category.

Additionally, according to data released by Scopus (Elsevier), the Current Oncology received an updated CiteScore™ of 3.3, an increase of 27% compared with the 2022 metric. Current Oncology’s CiteScore ranks Q3 (238 among 404 titles) in the “Oncology” category.

For further statistics, please visit https://www.mdpi.com/journal/curroncol/stats. For more information about MDPI flagship journals' citation metrics, please see here.

At MDPI, our mission is simple yet powerful, and we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.

Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.

Current Oncology Editorial Office

Cancer Immunotherapy Awareness Month, taking place in June, is dedicated to raising awareness of the importance and potential of immunotherapy in the treatment of cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of cancer immunotherapy, published in Current Oncology (ISSN: 1718-7729). We hope that this announcement will provide useful information regarding this field.

“Immunotherapy in Gastric Cancer”
by Anica Högner and Markus Moehler
Curr. Oncol. 2022, 29, 1559-1574. https://doi.org/10.3390/curroncol29030131
Available online: https://www.mdpi.com/1718-7729/29/3/131

“The Role of Immunotherapy in Pancreatic Cancer”
by Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley and Marcus S. Noel
Curr. Oncol. 2022, 29, 6864-6892. https://doi.org/10.3390/curroncol29100541
Available online: https://www.mdpi.com/1718-7729/29/10/541

“Immunotherapy in Squamous Cell Cancer of the Esophagus”
by Peter Thuss-Patience and Alexander Stein
Curr. Oncol. 2022, 29, 2461-2471. https://doi.org/10.3390/curroncol29040200
Available online:  https://www.mdpi.com/1718-7729/29/4/200

“Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma”
by Jong Chul Park, Hari N. Krishnakumar and Srinivas Vinod Saladi
Curr. Oncol. 2022, 29, 4185-4198. https://doi.org/10.3390/curroncol29060334
Available online:  https://www.mdpi.com/1718-7729/29/6/334

“Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients”
by Justin Tong, Adi Kartolo, Cynthia Yeung, Wilma Hopman and Tara Baetz
Curr. Oncol. 2022, 29, 7953-7963. https://doi.org/10.3390/curroncol29100629
Available online:  https://www.mdpi.com/1718-7729/29/10/629

“Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review”
by Raida M. Khwaja and Quincy S.-C. Chu
Curr. Oncol. 2022, 29, 479-489. https://doi.org/10.3390/curroncol29020043
Available online:  https://www.mdpi.com/1718-7729/29/2/43

The list of relevant Special Issues is as follows:
Immunotherapy for Gastrointestinal Cancer
Guest Editor: Dr. Patrick M. Boland
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Immunotherapy_GI

Immune Checkpoint Inhibitors in Cancer Therapy: State of the Art and Future Perspectives
Guest Editors: Dr. Aparna Jayachandran, Prof. Dr. George Kannourakis and Dr. Prashanth Prithviraj
Available Online: https://www.mdpi.com/journal/curroncol/special_issues/Immune_Checkpoint_Inhibitors_Cancer_Therapy

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.
Current Oncology Editorial Office

MDPI is pleased to announce the inclusion of 237 journals in the 2024 release of the Journal Citation Reports (JCR) and share the key results (see above).

This year, journals covered in the Emerging Sources Citation Index (ESCI) received category ranks together with journals in the Science Citation Index Expanded (SCIE) and Social Sciences Citation Index (SSCI). Overall, 139 MDPI journals indexed in ESCI are included in the new unified rankings for the first time.

Enhanced Comparability of Data

According to Clarivate, "the creation of unified category rankings [provides] a simpler and more complete category view for the evaluation of journal performance. [...] The category-first approach simplifies journal performance assessment with a holistic view of all journals in each subject category."

We are thrilled to announce that 72% of our ranked MDPI journals (171 of 237) are above average, in Q1 or Q2. Twenty-nine of our journals received their first Impact Factor this year, accounting for more than 5% of the journals accepted into the Web of Science last year.

MDPI Journals Ranked in JCR

The following data includes all MDPI journals indexed in SCIE, SSCI, ESCI and AHCI.

Source: 2023 Journal Impact Factors, Journal Citation Reports ^TM (Clarivate, 2024)

About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 440 fully open access titles.

June is Cancer Survivors Month, which is a month-long observance that celebrates the strength, resilience, and triumph of those who have battled cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in fields concerning cancer survivors, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information regarding this field.

“A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring”
by Corina J. G. van den Hurk, Floortje Mols, Manuela Eicher, Raymond J. Chan, Annemarie Becker, Gijs Geleijnse, Iris Walraven, Annemarie Coolbrandt, Maryam Lustberg, Galina Velikova et al.
Curr. Oncol. 2022, 29(6), 4370-4385; https://doi.org/10.3390/curroncol29060349
Available online: https://www.mdpi.com/1718-7729/29/6/349

“Sexual Function in Women Survivors of Hematologic Malignancy after Autologous Hematopoietic Stem Cell Transplantation”
by Ioanna Tsatsou, Kyriaki Mystakidou, Theodoula Adamakidou, Theocharis Konstantinidis, Ioannis Kalemikerakis, Antonis Galanos and Ourania Govina
Curr. Oncol. 2023, 30(3), 2916-2927; https://doi.org/10.3390/curroncol30030223
Available online: https://www.mdpi.com/1718-7729/30/3/223

“’Beyond Cancer’ Rehabilitation Program to Support Breast Cancer Survivors to Return to Health, Wellness and Work: Feasibility Study Outcomes”
by Dianne M. Sheppard, Moira O’Connor, Michael Jefford, Georgina Lamb, Dorothy Frost, Niki Ellis and Georgia K. B. Halkett
Curr. Oncol. 2023, 30(2), 2249-2270; https://doi.org/10.3390/curroncol30020174
Available online: https://www.mdpi.com/1718-7729/30/2/174

“Personality Traits and Coping Strategies Relevant to Posttraumatic Growth in Patients with Cancer and Survivors: A Systematic Literature Review”
by Klara Knauer, Anne Bach, Norbert Schäffeler, Andreas Stengel and Johanna Graf
Curr. Oncol. 2022, 29(12), 9593-9612; https://doi.org/10.3390/curroncol29120754
Available online: https://www.mdpi.com/1718-7729/29/12/754

“Assessing the Relationship between Socioeconomic Status, Race, and Psychological Distress in Cancer Survivors: A Population Based Study”
by Ikechukwu Chidobem, Fan Tian, Chisom Mgbodile, Francis Mgbodile, Tahereh Orouji Jokar, Esther Ogbuokiri and Nazia Khan
Curr. Oncol. 2022, 29(4), 2575-2582; https://doi.org/10.3390/curroncol29040211
Available online: https://www.mdpi.com/1718-7729/29/4/211

“Clinical Management of Financial Toxicity–Identifying Opportunities through Experiential Insights of Cancer Survivors, Caregivers, and Social Workers”
by Christopher J. Longo, Louisa G. Gordon, Rebecca L. Nund, Nicolas H. Hart, Laisa Teleni, Carla Thamm, Olivia Hollingdrake, Fiona Crawford-Williams, Bogda Koczwara, Tamara Ownsworth et al.
Curr. Oncol. 2022, 29(10), 7705-7717; https://doi.org/10.3390/curroncol29100609
Available online: https://www.mdpi.com/1718-7729/29/10/609

You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.

Current Oncology Editorial Office

On UNESCO’s 2024 Oceans Day, MDPI encourages the scientific community to increase the accessibility of ocean research to accelerate ocean conservation.

Basel, Switzerland, June 7, 2024: MDPI, a leading open access (OA) publisher, is proud to announce its active support for World Oceans Day 2024, celebrated under UNESCO’s Ocean Decade framework. MDPI’s CEO, Stefan Tochev hopes that “the latest ocean research can be made freely accessible to help empower scientists and communities at large to save our oceans,” under UNESCO’s Ocean Decade until 2030.

Open Access: A Catalyst for Ocean Action

MDPI’s presence at the UNESCO Ocean Decade Conference 2024 highlights our unwavering commitment to using OA to advance ocean science, support research communities, and promote sustainable ocean management.

"Our involvement in the UNESCO Ocean Decade Conference underscores MDPI's commitment to the underfunded Ocean SDG. By promoting OA to scientific articles and books on SDGs, we aim to inspire critical actions," said Tochev. "Our initiatives, like the World Sustainability Award and Emerging Sustainability Award, further demonstrate our dedication to advancing sustainability.”

Showcasing MDPI’s Contributions to Ocean Research

Over the past three years, MDPI has published 30,000 papers focused on ocean research and related topics. Key MDPI journals contributing to this body of work include:

• Journal of Marine Science and Engineering (4.9k papers)
• Remote Sensing (2.6k papers)
• Sustainability (2k papers)
• International Journal of Molecular Sciences (IJMS) (1.7k papers)
• Marine Drugs (1.5k papers)
• Water (1.5k papers)

These publications highlight MDPI’s contributions to ocean science, reinforcing our role in the broader sustainability agenda by promoting blue innovation and economy.

Additionally, MDPI has launched Oceans, an international, peer-reviewed forum specifically aimed at publishing studies related to all branches of oceanography with an emphasis on the functioning of the ocean and the sustainable use of its resources and ecosystem services.

Affirming MDPI’s Commitment to Ocean Science

MDPI’s commitment to OA is pivotal in addressing critical global challenges, from climate change to ocean sustainability. Our efforts resonate with Outcome 4 of the UNESCO Ocean Decade action roadmap: an accessible ocean with open and equitable access to data, information, technology, and innovation. By aligning with UNESCO’s goals, MDPI continues to contribute to shaping a sustainable future for our oceans, reinforcing our position as a forward-thinking publisher dedicated to environmental stewardship and scientific excellence.

For more information, contact Rui Duarte at rui.duarte@mdpi.com or +41764313242.

About MDPI